Loading
companiesCompany
Heidelberg Pharma
Heidelberg Pharma is a German company building antibody-drug conjugates around amanitin, a toxin from the death cap mushroom that kills cells by blocking RNA polymerase II, with its lead candidate HDP-101 in multiple myeloma.
Also called: Heidelberg Pharma AG
Overview
Heidelberg Pharma, based in Ladenburg near Heidelberg and listed in Frankfurt, develops antibody-targeted amanitin conjugates (ATACs): the payload amanitin inhibits RNA polymerase II, a mechanism distinct from the microtubule and DNA-damaging payloads of most ADCs and active in slowly dividing cells. Its lead candidate HDP-101 targets BCMA in relapsed multiple myeloma, and the platform is licensed to partners including Takeda. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov, from earlier programmes.
Similar pages
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda, Multiple myeloma.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares BCMA, Multiple myeloma.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Takeda, Antibody-drug conjugate (ADC).
- CompanyCartesian Therapeutics
Shares BCMA, Multiple myeloma.
- TreatmentAZD4045
Shares BCMA, Multiple myeloma.
- CompanyKelonia Therapeutics
Shares BCMA, Multiple myeloma.
- PersonNoopur Raje
Shares BCMA, Multiple myeloma.
- CompanyAurigene Oncology
Shares BCMA, Multiple myeloma.